Condition

Spinal Cord Injury at C5-C7 Level clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Spinal Cord Injury at C5-C7 Level clinical trials that are recruiting, at sites in 2 countries (most in United States (2), Canada (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Spinal Cord Injury at C5-C7 Level clinical trials

StudyPhaseWhereStatusRegistered
Testing spinal stimulation methods for improving motor function in spinal cord injury patients — Winnipeg, Manitoba and 1 other locations Recruiting Feb 22, 2024
Assessment of a neuroprosthesis device for hand function in spinal cord injury patients — Cleveland, Ohio Recruiting May 18, 2023
Neuroprosthetic system to restore motor function in spinal cord injury — Cleveland, Ohio Recruiting Dec 31, 2014

All recruiting trials (3)

Related topics

Spinal Cord InjuriesSpinal Cord Injury Cervical

Quick answers

How many Spinal Cord Injury at C5-C7 Level clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in United States (2 trials), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.